News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
354,423 Results
Type
Article (20170)
Company Profile (87)
Press Release (334150)
Multimedia
Podcasts (51)
Webinars (6)
Section
Business (89662)
Career Advice (1349)
Deals (17616)
Drug Delivery (77)
Drug Development (61590)
Employer Resources (62)
FDA (9264)
Job Trends (7586)
News (175360)
Policy (15297)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Pharm Country Standard (2)
Academia (1234)
Academic (1)
Accelerated approval (38)
Adcomms (16)
Allergies (126)
Alliances (17887)
ALS (142)
Alzheimer's disease (1233)
Antibody-drug conjugate (ADC) (278)
Approvals (9630)
Artificial intelligence (293)
Autoimmune disease (171)
Automation (20)
Bankruptcy (139)
Best Places to Work (6369)
BIOSECURE Act (8)
Biosimilars (140)
Biotechnology (54)
Bladder cancer (152)
Brain cancer (52)
Breast cancer (619)
Cancer (4272)
Cardiovascular disease (354)
Career advice (1080)
Career pathing (23)
CAR-T (200)
CDC (19)
Celiac Disease (1)
Cell therapy (513)
Cervical cancer (29)
Clinical research (55279)
Collaboration (1026)
Company closure (1)
Compensation (544)
Complete response letters (40)
COVID-19 (2309)
CRISPR (50)
C-suite (377)
Cystic fibrosis (108)
Data (6033)
Decentralized trials (1)
Denatured (5)
Depression (109)
Dermatology (48)
Diabetes (480)
Diagnostics (3625)
Digital health (23)
Diversity (3)
Diversity, equity & inclusion (8)
Drug discovery (167)
Drug pricing (95)
Drug shortages (23)
Duchenne muscular dystrophy (179)
Earnings (56817)
Editorial (29)
Employer branding (11)
Employer resources (54)
Events (57716)
Executive appointments (365)
FDA (11849)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (20)
Funding (967)
Gene editing (117)
Generative AI (23)
Gene therapy (439)
GLP-1 (930)
Government (2515)
Grass and pollen (6)
Guidances (368)
Healthcare (9704)
HIV (62)
Huntington's disease (39)
IgA nephropathy (79)
Immunology and inflammation (213)
Immuno-oncology (64)
Indications (136)
Infectious disease (2522)
Inflammatory bowel disease (143)
Inflation Reduction Act (5)
Influenza (95)
Intellectual property (171)
Interviews (248)
IPO (10265)
IRA (22)
Job creations (1478)
Job search strategy (921)
JPM (41)
Kidney cancer (18)
Labor market (59)
Layoffs (308)
Leadership (24)
Legal (2501)
Liver cancer (70)
Longevity (13)
Lung cancer (609)
Lymphoma (361)
Machine learning (21)
Management (17)
Manufacturing (429)
MASH (163)
Medical device (6616)
Medtech (6652)
Mergers & acquisitions (8048)
Metabolic disorders (1221)
mRNA (101)
Multiple sclerosis (144)
NASH (18)
Neurodegenerative disease (291)
Neuropsychiatric disorders (74)
Neuroscience (2283)
Neurotech (1)
NextGen: Class of 2026 (2667)
Non-profit (1867)
Now hiring (21)
Obesity (589)
Opinion (128)
Ovarian cancer (150)
Pain (164)
Pancreatic cancer (194)
Parkinson's disease (277)
Partnered (18)
Patents (295)
Patient recruitment (446)
Peanut (48)
People (16361)
Pharmaceutical (25)
Pharmacy benefit managers (10)
Phase 1 (15728)
Phase 2 (27229)
Phase 3 (17832)
Pipeline (5764)
Policy (107)
Postmarket research (1587)
Preclinical (5270)
Press Release (30)
Prostate cancer (225)
Psychedelics (36)
Radiopharmaceuticals (194)
Rare diseases (726)
Real estate (1767)
Recruiting (31)
Regulatory (13768)
Reports (37)
Research institute (1213)
Resumes & cover letters (260)
Rett syndrome (30)
RNA editing (9)
RSV (60)
Schizophrenia (136)
Series A (142)
Series B (117)
Service/supplier (5)
Sickle cell disease (80)
Special edition (20)
Spinal muscular atrophy (148)
Sponsored (31)
Startups (1364)
State (2)
Stomach cancer (18)
Supply chain (57)
Tariffs (44)
The Weekly (46)
Vaccines (739)
Venture capital (40)
Weight loss (390)
Women's health (62)
Worklife (13)
Date
Today (6)
Last 7 days (460)
Last 30 days (1699)
Last 365 days (20354)
2026 (5300)
2025 (20492)
2024 (22006)
2023 (24444)
2022 (29984)
2021 (32062)
2020 (30534)
2019 (22702)
2018 (17293)
2017 (17519)
2016 (15334)
2015 (18689)
2014 (13379)
2013 (9816)
2012 (10616)
2011 (11095)
2010 (9732)
Location
Africa (419)
Alabama (51)
Alaska (1)
Arizona (124)
Arkansas (5)
Asia (22987)
Australia (4119)
California (7943)
Canada (2263)
China (937)
Colorado (310)
Connecticut (388)
Delaware (254)
Europe (51466)
Florida (1096)
Georgia (264)
Hawaii (2)
Idaho (29)
Illinois (511)
India (50)
Indiana (354)
Iowa (15)
Japan (366)
Kansas (61)
Kentucky (35)
Louisiana (27)
Maine (42)
Maryland (909)
Massachusetts (5715)
Michigan (160)
Minnesota (351)
Mississippi (6)
Missouri (79)
Montana (17)
Nebraska (7)
Nevada (85)
New Hampshire (46)
New Jersey (2343)
New Mexico (4)
New York (2241)
North Carolina (827)
North Dakota (3)
Northern California (3921)
Ohio (186)
Oklahoma (3)
Oregon (20)
Pennsylvania (1510)
Puerto Rico (23)
Rhode Island (20)
South America (581)
South Carolina (22)
Southern California (3255)
Tennessee (86)
Texas (1280)
United States (27589)
Utah (195)
Vermont (1)
Virginia (162)
Washington D.C. (39)
Washington State (617)
West Virginia (1)
Wisconsin (62)
354,423 Results for "2".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cardiovascular disease
Kardigan Blood Pressure Drug Proves Hypothesis Despite Split Phase 2 Readout
While tonlamarsen missed one of two co-primary endpoints, Kardigan says the drug has shown a clinically meaningful effect on blood pressure, supporting advancement into Phase 2b.
March 30, 2026
·
2 min read
·
Annalee Armstrong
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
March 20, 2026
·
2 min read
·
Tristan Manalac
Insights
HER2’s Digital Rebirth Is Unlocking the Full Potential of ADCs
As next-generation antibody-drug conjugates reshape cancer care, digital pathology and artificial intelligence are transforming how HER2 is measured. The advances aim to help clinicians identify low and ultra-low expressors, match patients to the right therapies and make more precise treatment decisions.
February 10, 2026
·
3 min read
·
Jennifer C. Smith-Parker
Pipeline
Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy
Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”
February 5, 2026
·
2 min read
·
Tristan Manalac
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe and Jennifer Fakish at Danaher Corporation. They discuss how antibody drug conjugates (ADCs) are transforming cancer care. With AI-powered pathology, doctors can now measure HER2 more precisely to match patients with the best treatments.
February 12, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Press Releases
Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG
April 2, 2026
·
3 min read
Press Releases
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
March 31, 2026
·
5 min read
Press Releases
Akeso Advances “IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab
March 25, 2026
·
6 min read
Press Releases
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 year overall survival
October 10, 2025
·
6 min read
Press Releases
Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes
March 25, 2026
·
6 min read
1 of 35,443
Next
